Business Wire

Alipay Enables In-Store Payment Functionality in China for AR Glasses in Collaboration with Rokid to Build Immersive Commerce

18.6.2025 03:27:00 EEST | Business Wire | Press release

Share

Rokid, a pioneer in augmented reality (AR), today launched Rokid Glasses, its latest AR device. In China, the product supports in-store payments facilitated by Alipay’s digital payment technology and multidimensional risk control solution for AR glasses, providing a seamless and secure payment experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617845457/en/

Rokid partners with Alipay to launch China’s first AR glasses with in-store payment capabilities.

According to Rokid, the product will begin rolling out to users starting in June 2025, with over 250,000 units already ordered.

How Payment via AR Glasses Works:

  1. Users link their Alipay account via the Rokid app and enable voice verification.
  2. In stores, they say: “Rokid, pay 10 RMB.”
  3. The glasses scan the merchant’s Alipay QR code.
  4. Users confirm by voice, with payment details shown on the display.

Advantages of Payment via AR Glasses:

  1. Transactions complete in seconds vs. 20-30 seconds for phone-based QR payments.
  2. Hands-free operation—no need to handle a smartphone.

“Equipping Rokid Glasses with payment capabilities brings users a smoother and more intuitive experience, while also ushering the AI glasses industry into the era of payment. We believe this will set a new benchmark for the industry. Behind this innovation is close collaboration with Alipay on both payment and risk technologies. Looking ahead, we will continue to explore new experiences together,” said Zhu Mingming, Founder and CEO of Rokid.

“Rokid Glasses deliver a brand-new user experience. Alipay will fully support the growth of emerging industries and continue to create more value for users,” said Zhang Aijuan, Vice President of Ant Group and Rotating President of the Digital Payment Business Unit.

The integration of payment functions into AR glasses points to a future of more seamless and intuitive commerce. In the coming years, this technology could enable people to complete transactions simply by looking at or gesturing toward a product, removing friction from both physical and digital shopping.

It may support interactive product discovery—letting users access real-time information, virtual try-ons, or personalized recommendations—and make it possible to pay instantly without reaching for a phone or wallet. For businesses, this opens up new ways to engage customers through immersive experiences and location-specific offers.

Alipay continues to innovate payment technology as a merchant’s gateway to customer engagement in borderless commerce. In 2024, Alipay Tap! was launched to allow users to make payments simply by tapping their unlocked phone against a merchant terminal or an Alipay Tap! Tag—no need to open an app, scan a code, or navigate through multiple screens. As of April 2025, Alipay Tap! had already attracted over 100 million users.

About Rokid
Rokid is a product-oriented platform company dedicated to human-computer interaction for over a decade. As pioneers of AR, Rokid devotes itself to the R&D of hardware and software products for AR headsets and ecological architecture. The magic of AR leaves nobody behind. Rokid has successively been rated as the "High-tech Enterprise of Zhejiang Province" and "National High-tech Enterprise," and its related products have been rated as the best wearable devices. Rokid has won the Las Vegas CES Innovation Award for three consecutive years and the German IF Design Award five times.

About Alipay
As the world becomes increasingly digital, Alipay has evolved from a trusted e-wallet into an all-in-one digital platform for daily services, connecting more than one billion consumers to over 80 million merchants across China. Alipay offers users a secure, seamless mobile payment experience and integrates over 10,000 services across sectors like travel, healthcare, tourism, and entertainment. With digital tools like Alipay Tap!, mini-programs, lifestyle accounts, Alipay enables merchants, institutions, and independent software vendors (ISVs) to enhance operational efficiency and effectiveness. In addition, Alipay is developing a new AI-driven open platform by integrating AI agents to deliver smarter, more personalized services to its users as well as facilitating the digital transformation of the service sector.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250617845457/en/

Contacts

Media Inquiries
Yinan Duan
globalcomms@antgroup.com

Yuriko
yu.ge@rokid.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye